During the past decade, University of Rochester School of Medicine conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 10 clinical trials were completed, i.e. on average, 111.1% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 7 clinical trials were completed. i.e. 175% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Rochester School of Medicine" #1 sponsor was "University of Rochester" with 6 trials, followed by "Genzyme, a Sanofi Company" with 3 trials sponsored, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Rochester School of Medicine" #1 collaborator was "Rare Diseases Clinical Research Network" with 3 trials as a collaborator, "University of Rochester" with 3 trials as a collaborator, "Office of Rare Diseases (ORD)" with 2 trials as a collaborator, "American College of Clinical Pharmacy" with 1 trials as a collaborator and "Brigham and Women's Hospital" with 1 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "University of Rochester School of Medicine" are "Fabry Disease" (3 trials), "Andersen-Tawil Syndrome" (2 trials), "Breast Cancer" (2 trials), "Facioscapulohumeral Muscular Dystrophy" (2 trials) and "ADHD" (1 trials). Many other conditions were trialed in "University of Rochester School of Medicine" in a lesser frequency.

Most popular intervention types in "University of Rochester School of Medicine" are "Drug" (20 trials), "Biological" (7 trials), "Device" (4 trials), "Other" (4 trials) and "Behavioral" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "ACE-083" (2 trials), "Fabrazyme (agalsidase beta)" (2 trials), "10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)" (1 trials) and "15 mg fampridine-SR (4-aminopyridine, 4-AP)" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Rochester School of Medicine" are 34 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "University of Rochester School of Medicine". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in University of Rochester School of Medicine, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in University of Rochester School of Medicine, 5 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 7 trials that are defined as “Not Applicable".